Primary Care Rx Market Offers Second-Rate Return On Investment, Bristol Says
This article was originally published in The Pink Sheet Daily
Executive Summary
The sales and marketing investment required to compete in the primary care market means that no drug company can perform well by remaining in the category, CFO Bonfield asserts. To maintain a presence in primary care, Bristol will increasingly turn to development partners, as it did to Merck for its dual PPAR agonist muraglitazar.
You may also be interested in...
Primary Care Sales Force Downsizing Will Continue, Bristol Says
Bristol-Myers Squibb expects additional downsizing of its primary care sales force as it shifts its product portfolio to specialty care, Exec VP Donald Hayden told analysts July 29
Primary Care Sales Force Downsizing Will Continue, Bristol Says
Bristol-Myers Squibb expects additional downsizing of its primary care sales force as it shifts its product portfolio to specialty care, Exec VP Donald Hayden told analysts July 29
Rx Marketing Compliance Easier On Specialty Care Marketers, Bristol Exec Says
Compliance with the HHS Office of Inspector General marketing guidelines is made easier by operating outside the highly competitive primary care market, Bristol-Myers Squibb CFO Andrew Bonfield said